Cancer-associated fibroblast activation protein in Appalachian women with uterine cervix cancer

Category	Detail
Condition
Key Mechanisms
Target Population	Women with persistent, recurrent, or metastatic uterine cervix cancer, particularly those in Appalachian regions with high incidence rates.
Care Setting

82% of uterine cervix cancer tumors expressed FAP, indicating potential for targeted therapies.
59% of tumors scored an immunoreactive score (IRS) of six or higher, correlating with treatment response.
Stage IVB and metastatic tumors had the highest FAP expression, suggesting urgency for targeted interventions.
Study supports the use of FAP as a biomarker for targeted radiopharmaceutical therapy, enhancing treatment personalization.
Clinical trial NCT06710756 is underway for metastatic uterine cervix cancer patients, focusing on FAP expression.

Assess FAP expression in uterine cervix cancer tumors using immunohistochemistry to guide treatment.

Consider [212Pb]Pb-PSV-359 therapy for patients with high FAP expression, as it may improve outcomes.

Monitor FAP immunoreactivity as a potential biomarker for treatment response and adjust therapy accordingly.

Patients with advanced-stage disease have a high risk of persistent or recurrent disease; proactive management is essential.

FAP expression may guide the selection of patients for targeted radiopharmaceutical therapies, improving treatment efficacy.

Utilize automated immunohistochemical staining for accurate FAP assessment and ensure consistency in results.
Incorporate FAP IRS scoring in clinical trial eligibility criteria to enhance patient selection.

Clinical Scorecard: Activation of Fibroblast Activation Protein in Appalachian Women Diagnosed with Cervical Cancer